LitAlert ~~

    • Genome-wide Analysis of Rare Haplotypes Associated with Breast Cancer Risk.
    • Wang F, Moon W, Letsou W, Sapkota Y, Wang Z, Im C, Baedke JL, Robison L, Yasui Y.
    • Cancer Res. 2022 Nov 10:CAN-22-1888. doi: 10.1158/0008-5472.CAN-22-1888. Epub ahead of print.
    • Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics.
    • Jia G, Ping J, Shu X, Yang Y, Cai Q, Kweon SS, Choi JY, Kubo M, Park SK, Bolla MK, Dennis J, Wang Q, Guo X, Li B, Tao R, Aronson KJ, Chan TL, Gao YT, Hartman M, Ho WK, Ito H, Iwasaki M, Iwata H, John EM, Kasuga Y, Kim MK, Kurian AW, Kwong A, Li J, Lophatananon A, Low SK, Mariapun S, Matsuda K, Matsuo K, Muir K, Noh DY, Park B, Park MH, Shen CY, Shin MH, Spinelli JJ, Takahashi A, Tseng C, Tsugane S, Wu AH, Yamaji T, Zheng Y, Dunning AM, Pharoah PDP, Teo SHKang D, Easton DF, Simard J, Shu X, Long J, Zheng W.
    • Am J Hum Genet. 2022 Nov 9:S0002-9297(22)00459-1. doi: 10.1016/j.ajhg.2022.10.011. Epub ahead of print.

    •• Research news: Largest Genetic Risk Study in Breast Cancer Reveals Differences Between Asian and European Populations. (Inside Precision Medicine)

    • Study Suggests a PARP Inhibitors Has Wider Cancer Applications.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 9.

    •• Original research:

    A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.